Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias

Contributions to Nephrology

Volumn 153, Issue , 2007, Pages 44-65

  Mayo, Mary M ^a   Johns, Gretchen Schaef ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; BLOOD; DISEASE COURSE; HUMAN; IMMUNOLOGY; MULTIPLE MYELOMA; PARAPROTEINEMIA; PLASMACYTOMA; REVIEW;

AMYLOIDOSIS; BENCE JONES PROTEIN; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PLASMACYTOMA;

EID: 33751520688     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000096760     Document Type: Review

References (77)

1. Kyle RA, Katzmann JA, Lust JA and Dispenzieri A: Clinical indications and applications of electrophoresis and immunofixation; in Rose NR, Hamilton RG and Detrick B (eds): Manual of Clinical Immunology, ed 6. ASM Press, 2002.
2. Keren DF, Alexanian R, Goeken JA, Gorevic PD, Kyle RA, Tomar RH: Guidelines for clinical and laboratory evaluation of patients with monoclonal gammopathies. Arch Pathol Lab Med 1999;123:106-107.
3. Kyle RA: Sequence of testing for monoclonal gammopathies: serum and urine assays. Arch Pathol Lab Med 1999;123:114-118.
4. Kyle RA, Gerta MA, Witzig TE, et al: Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003;78:21-33.
5. Durie BGM, Kyle RA, Belch A, Bensinger W, Bladé J, Boccadoro M, Child JA, Comenzo R, Djulbegovic B, Fantl D, Gahrton G, Harousseau J, Hungria V, Joshua D, Ludwid H, Mehta J, Rodriquez-Morales A, Morgan G, Nouel A, Oken M, Powels R, Roodman D, San Miguel J, Shimizu K, Singhal S, Sirohi B, Sonneveld P, Tricot G, Van Ness B: Myeloma management guidelines: a consensus report from the scientific advisors of the International Myeloma Foundation. Hematol J 2003;4:379-398.
6. Alexanian R, Weber D, Liu F: Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med 1999;123:108-113.
7. Bradwell AR, Mead GP, Carr-Smith HD: Amyloidosis and light chain deposition disease; in Serum Free Light Chain Analysis, ed 4.The Binding Site, 2006.
8. Katzmann JA, Clark RJ, Abraham RS, et al: Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002;48:1437-1444.
9. Blade J, Kyle RA: Nonsecretory myeloma, Immunoglobulin D myeloma and plasma cell leukemia. Hematol Oncol Clin North Am 1999;13:1259-1272.
10. Bence Jones H: Papers on chemical pathology. Lancet 1847;2:88-92.
11. Rosenfeld L: Henry Bence Jones (1813-1873): the best 'Chemical Doctor' in London. Clin Chem 1987;9:1687-1692.
12. Ouchterlony O: Antigen-antibody reactions in gels. IV. Types of reactions in coordinated systems of diffusion. Acta Pathol Microbiol Scand 1953;32:231-240.
13. Korngold L, Lapiri R: Multiple myeloma proteins. II. The antigenic relationship of Bence-Jones proteins to normal gamma-globulin and cancer multiple myeloma serum proteins. Cancer 1956;9:262-272.
14. Bradwell AR, Mead GP, Carr-Smith HD: Biology of immunoglobulin light chains; in Serum Free Light Chain Analysis, ed 4. The Binding Site, 2006.
15. Sölling K: Free light chains of immunoglobulins in normal serum and urine determined by radioimmunoassay. Scand J Clin Lab Invest 1975;35:407-412.
16. Cole PW, Durie BGM, Salmon SE: Immunoquantitation of free light chain immunoglobulins: applications in multiple myeloma. J Immunol Methods 1978;19:341-349.
17. Bradwell AR, Carr-Smith HD, Mead GP, et al: Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-680.
18. Tate J, Mollee P, Gill D: Serum free light chains for monitoring multiple myeloma. Br J Haematol 2005;128:405-406.
19. Mead GP, Carr-Smith H, Drayson M, et al: Response to: serum free light chains for monitoring multiple myeloma. Br J Haematol 2005;128:406-407.
20. Mead GP, Carr-Smith HD, Drayson M, et al: Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-354.
21. Kang S-Y, Suh J-T, Lee H-J, et al: Clinical usefulness of free light chain concentration as a tumor marker in multiple myeloma. Ann Hematol 2005;84:588-593.
22. Durie BGM, Harousseau J-L, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV: International uniform response criteria for multiple myeloma. Leukemia 2006;20:1465-1471.
23. Bradwell AR, Mead GP, Carr-Smith HD, Drayson MT: Serum test for assessment of patients with Bence-Jones myeloma. Lancet 2003;361:489-491.
24. Abraham RS, Clark RJ, Bryant SC, et al: Correlation of serum immunoglobulin free light chain quantitation with urine Bence Jones protein in Light Chain Myeloma. Clin Chem 2002;48:655-657.
25. Abraham RS, Katzmann JA, Clark RJ, et al: Quantitative analysis of serum free light chains: a new marker for the diagnostic evaluation of primary systemic amyloidosis. Am J Clin Pathol 2003;119:274-278.
26. Katzmann JA, Abraham RS, Dispenzieri A, et al: Diagnostic performance of quantitative κκ and λλ free light chain assays in clinical practice. Clin Chem 2005;51:878-881.
27. Gertz MA, Comenzo R, Falk RH, et al: Definition of organ involvement and treatment response in immunoglobulin light chain Amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol 2005;79:319-328.
28. Dispenzieri A, Lacy MQ, Katzmann JA: Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006;107:3378-3383.
29. Brockhurst I, Harris KPG, Chapman CS: Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay. Nephrology Dial Transplant 2005;20:1251-1253.
30. Drayson M, Tang LX, Drew R, et al: Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001;97:2900-2902.
31. Bradwell AR, Mead GP, Carr-Smith HD: Multiple myeloma; in Serum Free Light Chain Analysis, ed 4. The Binding Site, 2006.
32. Bradwell AR, Mead GP, Carr-Smith HD: Free light chain normal ranges and reference intervals; in Serum Free Light Chain Analysis, ed 4. The Binding Site, 2006.
33. Tate JR, Gill D, Cobcroft R, Hickman P: Practical considerations for the measurement of free light chains in serum. Clin Chem 2003;49:1252-1257.
34. Rajkumar SV, Kyle RA, Therneau TM, Clark RJ, Bradwell AR, Melton LJ III, Larson DR, Plevak MF, Katzmann JA: Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance. Br J Haematol 2004;127:308-310.
35. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, Melton LJ III: A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002;346:564-569.
36. Bradwell AR, Mead GP, Carr-Smith HD: Serum Free Light Chain Analysis, ed 4. Birmingham, UK, The Binding Site, Ltd., 2006, pp 153-155.
37. Kyle RA, Child JA, et al: Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Hematol J 2003;4(suppl):S31, p4.1.
38. Rajkumar SV, Dispenzieri A, Fonseca R, Lacy MQ, Geyer S, Lust JA, Kyle RA, Greipp PR, Gertz MA, Witzig TE: Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia 2001;15:1274-1276.
39. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, Dispenzieri A, Katzmann JA, Melton LJ III: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:1362-1369.
40. Saleun JP, Vicariot M, Deroff P, Morin JF: Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol 1982;35:63-68.
41. Weber DM, Wang LN, Delasalle KB, Smith T, Alexanian R: Risk factors for early progression of asymptomatic multiple myeloma. Hematol J 2003;4(suppl):S31, p4.2.
42. Walker BM, Figgs LW, Zahm SH: Environmental health issues. Differences in cancer incidence, mortality, and survival between African Americans and whites. Environ Health Perspect 1995;103(suppl 8):275-281.
43. Bergsagel D: The incidence and epidemiology of plasma cell neoplasms. Stem Cells 1995;13(suppl 12):1-9.
44. Landgren O, Gridley MS, Turesson I, Caporaso NE, Goldin LR, Baris D, Fears TR, Hoover RN, Linet MS: Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African-American and white veterans in the U.S. Blood 2005;106:Abstract #1541.
45. Baris D, Brown LM, Silverman DT, Hayes R, Hoover RN, Swanson GM, Dosemeci M, Schwartz AG, Liff JM, Schoenberg JB, Pottern LM, Lubin J, Greenberg RS, Fraumeni JF Jr: Socioeconomic status and multiple myeloma among US blacks and whites. Am J Public Health 2000;90:1277-1281.
46. Fritschi L, Siemiatycki J: Lymphoma, myeloma and occupation: results of a case-control study. Int J Cancer 1996;67:498-503.
47. Rettig MB, Ma HJ, Vesico RA, Põld M, Schiller G, Belson D, Savage A, Nishikubo C, Wu C, Fraser J, Said JW, Berenson JR: Kaposi's sarcoma-associated herpesvirus infection of the bone marrow dendritic cells from multiple myeloma patients. Science 1997;276:1851-1854.
48. MacKenzie J, Sheldon J, Morgan G, Cook G, Schultz TF, Jarrett RF: HHV-8 and multiple myeloma in the UK. Lancet 1997;356:1144-1145.
49. Marcelin A, Dupin N, Bouscary D, Bossi P, Cacoub P, Ravaud P, Calvez V: HHV-8 and multiple myeloma in France. Lancet 1997;350:1144.
50. Bladé J, Rosiñol L, Cibeira MT: The evolving versus the non-evolving nature of asymptomatic monoclonal gammopathies: monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Hematol J 2005;90:12.
51. Rosiñol L, Bladé J, Cibeira MT, Montoto S, Esteve J, Rozman M, Fililla X, Montserrat E: Monoclonal gammopathy of undetermined significance (MGUS): predictors of outcome and recognition of an evolving type. Blood 2005;106:Abstract #5052.
52. Rosiñol L, Bladé J, Esteve J, Aymerich M, Rozman M, Montoto S, Giné E, Nadal E, Filella X, Queralt R, Carrió A, Montserrat E: Smoldering multiple myeloma: natural history and recognition of an evolving type. Br J Haematol 2003;123:631-636.
53. Facon T, Avet-Loiseau H, Leleu X, Bataille R: Cytogenetic changes in the evolution of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM). Hematol J 2003;4(suppl):S32, p4.3.
54. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Dávila R, González-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR: The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003;102:2562-2567.
55. Debes-Marun CS, Dewald GW, Bryant S, Picken E, Santana-Dávila R, González-Paz N, Winkler JM, Kyle RA, Gertz MA, Witzig TE, Dispenzieri A, Lacy MQ, Rajkumar SV, Lust JA, Greipp PR, Fonseca R: Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma. Leukemia 2003;17:427-436.
56. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Oken MM, Blood E, Henderson K, Santana-Dávila R, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R: A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005;106:2156-2161.
57. Fonseca R, Bailey RJ, Ahmann J, Rajkuman SV, Hoyer JD, Lust JA, Kyle RA, Gertz MA, Greipp PR, Dewald GW: Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002;100:1417-1424.
58. Al Rayes MH, Rawstron AC, Morgan GJ, Davies FE: The bone marrow microenvironment influences the differential chemokine receptor expression of normal and neoplastic plasma cells. Blood 2005;105:4895-4896.
59. Rawstron AC, Fenton JAL, Ashcroft J, English A, Jones RA, Richards SJ, Pratt G, Owen R, Davies FE, Child JA, Jack AS, Morgan G: The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. Blood 2000;96:3880-3886.
60. Prabhala RH, Neri P, Tassone P, Bae JE, Shamas MA, Daley JF, Song W, Bertheau R, Chauhan D, Bachu RB, Thatte H, Anderson K, Munshi NC: Dysfunctional T regulatory cells in myeloma: molecular mechanisms of dysregulation. Blood 2005;106:Abstract #3462.
61. Martin-Acosta P, Sanchez-Massa D, Corbacho C, Montalban C, Bellas C: DNA methylation changes in plasma cell dyscrasias. Blood 2005;106:Abstract #1560.
62. Kimlinger TK, Witzig TE, Rajkumar SV: Expression of VEGF receptors on plasma cells: evidence of heterogeneity. Blood 2004;104:Abstract #3361.
63. Annibali O, Petrucci MT, Bartolozzi F, Levi A, Del Bianco P, Gullucci C, Foa R, Mandelli F, Avvisati G: Long term follow-up of 198 IgM monoclonal gammopathy of undetermined significance (MGUS). Blood 2004;104:Abstract #4859.
64. Cesana C, Klersy C, Barbarano L, Nosari AM, Crugnola M, Pungolino E, Gargantini L, Granata S, Valentini M, Morra E: Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin One 2002;20:1625-1634.
65. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ III, Bradwell AR, Clark RJ, Larson DR, Plevak MF, Dispenzieri A, Katzmann JA: Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005;106:812-817.
66. Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, Poser M, Mueller S, Ebeling P, Welt A, Buttkereit U, Opalka B, Flasshove M, Seeber S, Moritz T: Relationship between serum concentrations and urinary excretions of monoclonal free light chains (mFLC) detectable as Bence Jones protein (BJP) by immunofixation electrophoresis (IFE) in patients with multiple myeloma (MM). Blood 2005;106:Abstract #5060.
67. Kyle R, Therneau T, Rajkumar SV, Remstein E, Kurtin P, Larson D, Plevak M, Melton LJ III: Update on smoldering multiple myeloma. Hematol 2005;90, PL3.02:12-13.
68. Augustson BM, Reid SD, Mead GP, Drayson MT, Child JA, Bradwell AR: Serum free light chain levels in asymptomatic myeloma. Blood 2004;104:Abstract #4880.
69. Fonseca R, Bergsagel PL, Chesi M, Rajkumar SV, Kyle RA, Reeder C, Trent J, Carpten J, Kim S, Chng TH, Baker A, Gertz M, Al Masri A, Chng WJ, Ahmann GJ, Van Wier SA, Price-Troska T, Henderson K, Rempel R, Gonzalez-Paz N, Santana R, Debes-Marun C, Winkler JM, Greipp PR: Integration of genetics in a comprehensive pathogenesis model for myeloma. Hematol J 2005;90, PL2.01:4.
70. Kumar S, Rajkumar SV, Kyle RA, Lacy MQ, Dispenzieri A, Fonseca R, Lust JA, MA, Greipp PR, Witzig TE: Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. J Clin Oncol 2005;23:5668-5674.
71. Davies FE, Dring AM, Li C, Rawstron AC, Shammas MA, O'Connor SM, Fenton JAL, Hideshima T, Chauhan D, Tai IT, Robinson E, Auclair D, Rees K, Gonzalez D, Ashcroft AJ, Dasgupta R, Mitsiades C, Mitsiades N, Chen LB, Wong WH, Munshi NC, Morgan GJ, Anderson KC: Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 2003;102:4504-4511.
72. Rajkumar SV, Mesa RA, Fonseca R, Schroeder G, Plevak MF, Dispenzieri A, Lacy MQ, Lust JA, Witzig TE, Gertz MA, Kyle RA, Russell SJ, Greipp PR: Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002;8:2210-2216.
73. Rawstron AC, Davies FE, DasGupta R, Ashcroft AJ, Patmore R, Drayson MT, Owen RG, Jack AS, Child JA, Morgan GJ: Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood 2002;100:3095-3100.
74. Dimopoulos MA, Hamilas G: Solitary bone plasmacytoma and extramedullary plasmacytoma. Curr Treat Opt Oncol 2002;3:255-259.
75. Wilder RB, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R: Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone. Cancer 2002;94:1532-1537.
76. Dingli D, Kyle R, Rajkumar SV, Nowakowski GS, Larson DR, Bida JP, Gertz MA, Therneau TM, Melton LJ III, Dispenzieri A, Katzmann JA: Immunoglobulin free light chains and solitary plasmacytoma of bone. Blood First Edition Paper, prepublished online June 1, 2006;10.1182/blood-2006-04-015784.
77. Liebross RH, Ha CS, Cox JD, Weber D, Delasalle K, Alexanian R: Clinical course of solitary extramedullary plasmacytoma. Radiat Oncol 1999;52:245-249.